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The long-term follow-up of a homozygous variegate
porphyria patient revealed severe photosensitivity
accompanied by mild sensory neuropathy and IgA
nephropathy. A 35T to C transition in exon 2 (I12T)
and a 767C to G transversion in exon 7 (P256R) of
the protoporphyrinogen oxidase gene were identi®ed
from both alleles of the patient's cDNA and genomic
DNA samples. Both prokaryotic and eukaryotic
expression studies showed that the ®rst mutation in
the evolutionary conserved region resulted in a
decrease in the protoporphyrinogen oxidase activity
in contrast to the polymorphic substitution in exon
7, which affected the function of the enzyme assayed
in Escherichia coli but not COS-1 cells. Key words:
mutation/porphyria/protoporphyrinogen oxidase/variegate
porphyria. J Invest Dermatol 116:610±613, 2001
V
ariegate porphyria (VP) is a metabolic disorder of
heme biosynthesis resulting from diminished activity
of protoporphyrinogen oxidase (PPOX, EC1.3.3.4)
(Brenner et al, 1980). The disease is inherited as an
autosomal dominant trait, and is characterized by
photosensitivity and occasional acute neurovisceral attacks. The
cDNA (1.7 kb), the genomic structure (13 exons spread over
5.5 kb), and the chromosomal localization (1q22±23) for the
PPOX gene have been characterized (Nishimura et al, 1995;
Taketani et al, 1995, Roberts et al, 1996). To date around 80
mutations have been reported in the PPOX gene.
In Finland, the prevalence of VP has been estimated to be
1.3:100,000 (Mustajoki, 1980), and to date around 100 patients
drawn from a total of 19 families have been identi®ed. In one of these
families, a child was found to have a homozygous form of the disease
based on the low PPOX activity (around 10% of normal) in his
lymphocytes (Mustajoki et al, 1987). Ten other VP patients have
been described with similar manifestations of childhood onset of
severe photosensitivity accompanied by mental or growth retard-
ation (Hift et al, 1993; Roberts et al, 1998). Of those, six cases have
been heteroallelic (Meissner et al, 1996; Frank et al, 1998; Roberts et
al, 1998, Palmer et al, 2000) and two cases homoallelic with a varying
amount of residual PPOX activity (9±25%) (Roberts et al, 1998).
In this investigation we describe the long-term follow-up of the
homozygous patient and his relatives together with characterization
of the underlining molecular defect in the PPOX gene.1
MATERIALS AND METHODS
Patients A homozygous patient and 16 of his family members
(Fig 1A) and 17 other VP patients representing altogether 18 of the 19
Finnish VP families and 40 healthy unrelated Finnish controls were
investigated by DNA analysis. The diagnosis for VP was based on clinical
symptoms and on high fecal excretion of protoporphyrin and
coproporphyrin (Table I) (Li et al, 1986), and/or low lymphocyte
PPOX activity (Deybach et al, 1981) measured in at least one of the
family members. The diagnosis of the homozygous patient was based on
the low lymphocyte PPOX activity (0.4±0.6 nmol per mg protein), and
his asymptomatic parents, who were ®rst cousins, had half normal
activity (2.7 and 2.3 nmol per mg protein, normal 3.6±6.0, Mustajoki et
al, 1987).
DNA, RNA extractions and cDNA synthesis DNA was extracted
from white blood cells (Higuchi, 1989) and total RNA from Epstein±
Barr virus transfected lymphoblastoid cell lines (Chirgwin et al, 1979;
Sambrook et al, 1989). Complementary DNA was synthesized from
patients' total lymphoblast RNA by Superscript II RNase reverse trans-
criptase (Gibco BRL Life Technologies, MD) using random hexamers.
Sequencing of the genomic DNA and cDNA The cDNA samples
were ampli®ed using speci®c primers 5¢-TCATTTTCTCTCATCCC-
TACCTA-3¢ for exon 1 and 5¢-CATGAATGAGAGTTGGGGAT-
CAGCTG TTAG-3¢ for exon 13, 50 pmol each in 100 ml of a solution,
and 2 U of DNA polymerase (Dynazyme, Finnzymes, Finland). For
sequencing the genomic DNA, the DNA (200 ng) was ampli®ed using
XL PCR Kit (Perkin Elmer, NJ) and speci®c primer pairs: 5¢-TCA-
TTTTCTCTCATCCCTACCTA-3¢ for exon 1 and 5¢-CTTCCA-
GCGCCCTTCTGCCTGGAG-3¢ for exon 7, and 5¢-CCAGTCTCT-
TCCAAGCTGAGCAA-3¢ for exon 6 and 5¢-CATGAATGAGAG-
TTGGGGATCAGCTGTTAG-3¢ for exon 13. The temperature pro®le
in the polymerase chain reaction (PCR) was 2 min at 94°C for the ®rst
denaturation step, followed by 30 s at 94°C and 1±4 min at 63±67°C for
30 cycles. Restriction enzymes (BanI, MspI) were used according to the
manufacturers' instructions (New England Biolabs, MA), and the ampli-
®ed samples were puri®ed using Qiaquick PCR Puri®cation Kit (Qiagen,
CA) and sequenced using the Amplicycle Sequencing Kit (Perkin Elmer)
including 5 mCi a-33P-ATP (Amersham, U.K.) in each sample.
Prokaryotic and eukaryotic expression of PPOX mutations The
normal and mutant PPOX alleles were expressed in Escherichia coli using
the pUC18-vector (Pharmacia LKB Biotechnology, NJ). For the I12T
mutation, the mutagenesis was performed using a Chameleon double-
stranded site-directed mutagenesis kit (Stratagene Cloning Systems, CA)
and a sense primer (5¢-GTCGTGCTGGGCGGAGGCACCAGCGGC-
TTGGCCGCC-3¢). For the P256R mutation, an 810 bp PCR fragment
5¢-TTCGCCAGGCCTTGGCTGAGCGC-3¢ for exon 7 and 5¢-
CATGATCTAGAGTTGGGGATCAGC-3¢ were digested with XbaI.
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1Partly described earlier in Hepatology (1996) 23:1±90 (Abstr.)
The XbaI-XbaI fragment was ligated as a cassette into the corresponding
sites of the normal human PPOX-pUC18 or PPOX-I12T-pUC18. The
normal and mutant PPOX fragments were transferred to the
corresponding EcoRI sites of the modi®ed pCMV1-vector, pCMV5
(Anderson et al, 1989). COS-1 cells were transfected with pCMV5 or
the PPOX-pCMV5 or with the mutant constructs using 100 mM
chloroquine and CaCl2 precipitation (Sambrook et al, 1989). The PPOX
activity of Cos-1 cells alone was monitored with (3.7 6 0.5 nmol per
mg protein) or without chloroquine and CaCl2 precipitation in each
series (5.4 6 1.1 nmol per mg protein). Transfection ef®ciency was
controlled by excluding experiments in which the wild type PPOX
activity was less than a 2-fold increase compared with the background
activity. 0.2 mM ribo¯avin-containing media was added and the
transformed COS cells were incubated for 48 h before harvesting.
Assay of PPOX activity Transformed cells were lyzed with 300 ml
incubation buffer [150 mM Tris-HCl, 1 mM ethylenediamine tetraacetic
acid (EDTA), 61% (vol/vol) Tween 20], sonicated (three times 10 s),
and spun down for 5 min in a cold room, and 50 ml of the supernatant
was used for the PPOX activity assay (Deybach et al, 1981).
Protoporphyrinogen was prepared from protoporphyrin IX (Porphyrin
Products, Logan, UT) using sodium amalgam reduction just before use.
The protoporphyrinogen solution was diluted with 50 mM GSH
incubation buffer 1:1 (vol/vol) to avoid auto-oxidation and 10 ml was
used as a substrate in the reaction. The assays were carried out at 37°C
in the dark. At 5, 15, and 25 min, the samples were withdrawn and
mixed with 1 ml of 100 mM Tris-HCl, 1 mM EDTA, 0.1% Triton-X-
100 (vol/vol), pH 8.7, and 2 mM GSH. The formation of
protoporphyrin was determined by ¯uorescence using a Hitachi
spectro¯uorometer (wavelength of excitation 403 nm, emission 631 nm)
and the protein concentration was determined by the method of Bio-
RAD Protein Assay (Bio-Rad Laboratories, CA).
RESULTS AND DISCUSSION
Identi®cation and expression of PPOX mutations Sequen-
cing of the full-length cDNA and genomic DNA for PPOX from
the homozygous patient demonstrated a T to C transition in exon 2
at position 35 converting isoleucine to threonine (I12T) and
abolishing a BanI site (Fig 1B), and a C to G transversion in exon 7
at position 767 converting proline to arginine (P256R) and
abolishing MspI, HapII, and HpaII sites in both alleles. His parents,
who were ®rst cousins, and grandmothers were heterozygous for
the nucleic acid changes (Fig 1A). None of the 40 unrelated
healthy Finnish controls had the same point mutations. Of the
other 17 VP families studied, both mutations were identi®ed in one
additional family. The two families probably share a common
ancestor, as they originate from the central part of Finland.
Table II summarizes the PPOX activities of the expressed
normal alleles and the I12T and P256R mutations in E. coli and in
COS-1 cells. When crude cell extracts of plasmid-containing
cultures were assayed, the normal alleles were found to have high
levels of PPOX activity ± a mean 7-fold increase was measured
from bacterial cells and a mean 3-fold increase from mammalian
cells. In contrast to the normal constructs, the I12T substitution in
exon 2 resulted in a loss of function in both expression systems.
Furthermore, the results did not signi®cantly differ from those
obtained from the construct including both mutations identi®ed
(I12T + P256R). The P256R substitution in exon 7, which has
been identi®ed as a polymorphism in other Western European
populations (Whatley et al, 1999), resulted in less than half of the
normal PPOX activity in the prokaryotic expression system but the
activity was almost normal in eukaryotic expression. Ribo¯avin,
which is a cofactor for PPOX, was added to the transformed COS
cells and bacterial cell lysates for 48 h but no signi®cant increase in
PPOX activity was detected (data not shown). These results
demonstrate that mutant alleles are transcribed and that mutant
mRNAs are ef®ciently translated to an enzymatically impaired or
active protein, and furthermore that the stability of one of the
mutant polypeptides is comparable to that of the normal enzyme.
Table I. Results of biochemical porphyrin analysis of VP patientsa
Protoporphyrin
(SEM)
Coproporphyrin
(SEM)
Uroporphyrin
(SEM)
PBGb
(SEM)
d-ALAb
(SEM)
Red cells Feces Feces Urine Urine Urine Urine
(250±1050 nmol/l) (< 130 nmol/g) (< 100 nmol/g) (< 230 nmol/24 h) (< 35 nmol/24 h) (< 15 mmol/24 h) (< 50 mmol/24 h)
Family 1
Homozygous patient
with severe photo-
sensitivity, chronic
neuropathy and
renal failure
9501 6 851 489 6 49 103 6 30 351 6 67 173 6 45 6 6 2 1 6 3
Symptom-free
heterozygous
260 6 90 73 6 32 19 6 8 156 6 14 18 6 3 7 6 2 18 6 1
patients, n = 6
Family 2
Heterozygous patient
with 2 acute attacksc
783 521 6 19 379 6 174 213 6 37 83 6 37 12 6 1 25 6 3
Symptom-free 640 559 6 75 170 6 41 161 6 10 28 6 8 9 6 2 12 6 3
heterozygous patientc
aPoh-Fitzpatrick (1980).
bPBG, porphobilinogen; ALA, aminolevulinic acid; Mauzerall and Granick (1956).
cAt least 5 measurements in remission. Speci®c activity nmol/mg protein.
Table II. Expression of mutated protoporphyrinogen
oxidase in E.coli and COS cells
Plasmid cell cDNA Mean (SEM)a Rangea Percentage
pUC18 ± 6.2 6 1.1 1.8±13.3 0
E. coli HPPOX 47.0 6 3.7 21.2±71.0 100
I12T 5.5 6 1.3 2.2±10.4 0
P256R 20.7 6 3.3 3.9±35.7 35
I12T + P256R 7.4 6 0.9 3.8±10.7 3
pCMV5 ± 3.6 6 0.6 0.5±8.2 0
COS hPPOX 9.8 6 1.0 4.2±19.6 100
I12T 4.1 6 0.5 0.7±7.9 8
P256R 9.5 6 1.5 1.5±21.4 96
I12T + P256R 3.7 6 0.4 1.9±4.8 1
aAt least ®ve independent transfections and/or enzyme activity measurements.
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Clinical and biochemical characteristics of the homozygous
patient In contrast to his asymptomatic parents, the homozygous
patient developed a severe bullous skin disease post partum
followed by increased fragility and keloid-like scarring. From 5 y
of age he has had no severe acute photo reactions but blistering and
fragility with deep erosions complicated by bacterial infections
occur. Development of new scars has declined but they are still
abundant including dorsal parts of the hands, ears, neck, and the
scalp accompanied by partial alopecia (Fig 2). His ®ngers are
markedly shortened with ¯exion impairment. Early closure of the
phalangeal epiphyses was detected by radiographs. Mental status,
EEG, and CT of the head remain normal, but sensory
polyneuropathy was shown in ENMG and SEP especially in the
upper extremities. Fine motor coordination disturbances are
accompanied by minor verbal and visuospatial de®ciencies.
Raised intraocular pressure responding to a b-blocking agent and
myopia were detected as early as 6 y of age (vision 0.7). Increased
plasma (102 6 27 nmol per liter, normal <3 nmol per liter) and
erythrocyte protoporphyrin levels (70% zinc bound, Table I) were
associated with severe photosensitivity and skin fragility together
with microcytosis and hypochromia in his blood smear. Serum
creatinine level was constantly increased (mean 130 mmol per liter,
normal < 115 mmol per liter) accompanied by hematuria,
proteinuria, and increase of blood pressure (RR 140/90)
indicating renal failure. IgA nephropathy was con®rmed in renal
biopsy
The PPOX activities measured from the patient's and his
mother's lymphocytes with or without ribo¯avin substitution were
constantly low, and excretions of porphyrins and porphyrin
precursors were at the previous level (data not shown).
Figure 1. (A) Pedigree of the homozygous VP patient (j). Half black symbols are asymptomatic patients identi®ed by mutation and polymorphic site
analysis (M+/P+) or biochemical analysis or both. Healthy members of the family are identi®ed by mutation analysis (M±/P±). (B) Sequencing analysis
of the family members: grandmothers (I-1, I-2) and parents (II-1, II-2) are heterozygous for a 35T to C transition and a 767C to G transversion in the
PPOX gene. The severely affected child (III-1) is homozygous for the mutations and his brother (III-2) has a normal sequence.
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Ribo¯avin treatment did not alleviate clinical manifestations either.
Although he has been exposed to potential predisposing agents such
as infections, he has never experienced acute attacks indicating that
the clinical manifestations are more chronic neurologic and
cutaneous in origin. The heterozygous patients with I12T mutation
experience no cutaneous symptoms. Only one of them has
experienced two acute attacks in her youth due to use of
sulfonamides, suggesting a milder phenotype of this mutation at
the heterozygous state.
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Finland, the Paulo Foundation, and the Helsinki University Hospital Research
Funds.
REFERENCES
Anderson S, Davis DN, DaÈhlback H, JoÈrnvall H, Russell DW: Cloning, structure,
and expression of the mitochondrial cytochrome P-450 sterol hydroxylase, a
bile acid biosynthetic enzyme. J Biol Chem 264:8222±8229, 1989
Brenner DA, Bloomer RJ: The enzymatic defect in variegate porphyrin studies with
human cultured skin. New Engl J Med 302:765±769, 1980
Chirgwin JM, Przbyla AE, McDonald RJ, Rutter WJ: Isolation of biologically
activated ribonucleic acid from sources enriched in ribonuclease. Biochemistry
18:5294±5299, 1979
Deybach JC, de Verneuil H, Nordmann Y: The inherited enzymatic defect in
porphyria variegate. Hum Genet 58:425±428, 1981
Frank J, McGrath J, Lam H, Graham RM, Hawk JL, Christiano AM: Homozygous
variegate porphyria: identi®cation of mutations on both alleles of the
protoporphyrinogen oxidase gene in a severely affected proband. J Invest
Dermatol 110:452±455, 1998
Hift RJ, Meissner PN, Todd G, et al: Homozygous variegate porphyria: an evolving
clinical syndrome. Postgrad Med J 69:781±786, 1993
Higuchi R: Simple and rapid preparation of samples for PCR. In: Ehrlich H (ed.).
PCR Technology. Principles and Applications for DNA Ampli®cation. New York:
Stockton Press, 1989, pp. 31±38
Li F, Lim CK, Peters TJ: Analysis of urine and faecal porphyrins by HPLC coupled to
an advanced automated sample processor. Biomed Chromatogr 1:93±94, 1986
Mauzerall D, Granick S: The occurrence and determination of delta-aminolevulinic
acid and porphobilinogen in urine. J Biol Chem 219:435±436, 1956
Meissner PN, Dailey TA, Hift RJ, et al: AR59W mutation in human
protoporphyrinogen oxidase results in decreased enzyme activity and is
prevalent in South Africans with variegate porphyria. Nature Genet 13:95±97,
1996
Mustajoki P: Variegate porphyria: twelve years' experience in Finland. Q J Med
49:191±203, 1980
Mustajoki P, Tenhunen R, Niemi KM, Nordmann Y, KaÈaÈriaÈinen H, Norio R:
Homozygous variegate porphyria: a severe skin disease of infancy. Clin Genet
32:300±305, 1987
Nishimura K, Taketani S, Inokuchi H: Cloning of a human cDNA for
protoporphyrinogen oxidase by complementation in vivo of a hem G mutant
of Escherichia coli. J Biol Chemistry 270:8076±8080, 1995
Palmer RA, Elder GH, Keohane SG: Homozygous variegate porphyria: a compound
heterozygote with novel mutations in the PPOX gene. Br J Dermatol 143:42±
85, 2000
Poh-Fitzpatrick MB: A plasma porphyria ¯uorescent marker for variegate porphyria.
Arch Dermatol 116:543±547, 1980
Roberts AG, Whatley SD, Daniels J, et al: Partial characterization and assignment of
the gene for protoporphyrinogen oxidase and variegate porphyria to human
chromosome 1q23. Hum Mol Genet 4:2387±2390, 1996
Roberts AG, Puy H, Dailey TA, et al: Molecular characterization of homozygous
variegate porphyria. Hum Mol Gen 7:1921±1925, 1998
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. New
York: Cold Spring Harbour Laboratories, 1989
Taketani S, Inazawa J, Abe T, et al: The human protoporphyrinogen oxidase gene
(PPOX): organization and localization to chromosome 1. Genomics 29:698±
703, 1995
Whatley SD, Puy H, Morgan RR, Robreau AM, Roberts AG, Elder GH, Deybach
JC: Variegate porphyria in Western Europe: identi®cation of PPOX gene
mutations in 104 families, extent of allelic heterogeneity, absence of correlation
between phenotype and type of mutation. Am J Hum Genet 65:984±994, 1999
Figure 2. Severe bullous lesions, increased fragility and keloid-like
scarring of exposed skin. Fingers are markedly shortened.
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